1. Home
  2. CNTX vs UCB^I Comparison

CNTX vs UCB^I Comparison

Compare CNTX & UCB^I Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CNTX
  • UCB^I
  • Stock Information
  • Founded
  • CNTX 2015
  • UCB^I N/A
  • Country
  • CNTX United States
  • UCB^I United States
  • Employees
  • CNTX 9
  • UCB^I N/A
  • Industry
  • CNTX Biotechnology: Pharmaceutical Preparations
  • UCB^I
  • Sector
  • CNTX Health Care
  • UCB^I
  • Exchange
  • CNTX Nasdaq
  • UCB^I Nasdaq
  • Market Cap
  • CNTX 76.5M
  • UCB^I N/A
  • IPO Year
  • CNTX 2021
  • UCB^I N/A
  • Fundamental
  • Price
  • CNTX $1.02
  • UCB^I N/A
  • Analyst Decision
  • CNTX Strong Buy
  • UCB^I
  • Analyst Count
  • CNTX 4
  • UCB^I 0
  • Target Price
  • CNTX $7.38
  • UCB^I N/A
  • AVG Volume (30 Days)
  • CNTX 234.3K
  • UCB^I N/A
  • Earning Date
  • CNTX 11-06-2024
  • UCB^I N/A
  • Dividend Yield
  • CNTX N/A
  • UCB^I N/A
  • EPS Growth
  • CNTX N/A
  • UCB^I N/A
  • EPS
  • CNTX N/A
  • UCB^I N/A
  • Revenue
  • CNTX N/A
  • UCB^I N/A
  • Revenue This Year
  • CNTX N/A
  • UCB^I N/A
  • Revenue Next Year
  • CNTX N/A
  • UCB^I N/A
  • P/E Ratio
  • CNTX N/A
  • UCB^I N/A
  • Revenue Growth
  • CNTX N/A
  • UCB^I N/A
  • 52 Week Low
  • CNTX $0.89
  • UCB^I N/A
  • 52 Week High
  • CNTX $2.75
  • UCB^I N/A
  • Technical
  • Relative Strength Index (RSI)
  • CNTX 17.93
  • UCB^I N/A
  • Support Level
  • CNTX $1.17
  • UCB^I N/A
  • Resistance Level
  • CNTX $1.61
  • UCB^I N/A
  • Average True Range (ATR)
  • CNTX 0.11
  • UCB^I 0.00
  • MACD
  • CNTX -0.03
  • UCB^I 0.00
  • Stochastic Oscillator
  • CNTX 9.15
  • UCB^I 0.00

About CNTX Context Therapeutics Inc.

Context Therapeutics Inc is a clinical-stage biopharmaceutical company advancing medicines for solid tumors. The development team is advancing a pipeline of innovative therapies with a primary focus on treating female, hormone-dependent cancer, including breast, ovarian, and endometrial cancer. The company's preclinical program, CTIM-76, is an anti-Claudin 6 ("CLDN6") x anti-CD3 bispecific antibody ("bsAb") that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6.

Share on Social Networks: